Oncimmune Holdings Plc

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: GB00BYQ94H38
GBP
0.01
0 (-4.2%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

390.92 k

Shareholding (Dec 2021)

FII

8.25%

Held by 3 FIIs

DII

0

Held by 0 DIIs

Promoter

0.08%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

GBP 1 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.78

stock-summary
Return on Equity

145.81%

stock-summary
Price to Book

-0.53

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-92.72%
0%
-92.72%
6 Months
-94.6%
0%
-94.6%
1 Year
-93.39%
0%
-93.39%
2 Years
-97.48%
0%
-97.48%
3 Years
-99.21%
0%
-99.21%
4 Years
-99.44%
0%
-99.44%
5 Years
-98.02%
0%
-98.02%

Oncimmune Holdings Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
28.98%
EBIT Growth (5y)
10.21%
EBIT to Interest (avg)
-6.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.78
Sales to Capital Employed (avg)
0.39
Tax Ratio
12.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.53
EV to EBIT
-1.72
EV to EBITDA
-1.87
EV to Capital Employed
2.96
EV to Sales
2.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-171.87%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2021stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (8.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Oncimmune Holdings Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Aug'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Aug'23",
        "Aug'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.20",
          "val2": "2.30",
          "chgp": "-47.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-6.10",
          "chgp": "34.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "0.30",
          "chgp": "566.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-6.80",
          "chgp": "8.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,682.30%",
          "val2": "-2,717.20%",
          "chgp": "-96.51%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Aug'23stock-summary
Aug'23
Aug'22
Change(%)
Net Sales
1.20
2.30
-47.83%
Operating Profit (PBDIT) excl Other Income
-4.00
-6.10
34.43%
Interest
2.00
0.30
566.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.20
-6.80
8.82%
Operating Profit Margin (Excl OI)
-3,682.30%
-2,717.20%
-96.51%
USD in Million.
Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

stock-summaryCompany CV
About Oncimmune Holdings Plc stock-summary
stock-summary
Oncimmune Holdings Plc
Biotechnology
Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types. EarlyCDT-Lung is a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. EarlyCDT-Lung test is being used in the randomized trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland Early Childhood Longitudinal Study (ECLS) of over 12,000 high-risk smokers. It is also developing the EarlyCDT tests for other cancers, which include in particular the liver and ovarian cancers. It has sold over 145,000 tests in the United States and the United Kingdom.
Company Coordinates stock-summary
Company Details
MediCity, D6 Building, 1 Thane Road , NOTTINGHAM None : NG90 6BH
stock-summary
Tel: 44 115 7840500
stock-summary
Registrar Details